Compare BTOC & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTOC | KPRX |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 11.7M |
| IPO Year | 2023 | N/A |
| Metric | BTOC | KPRX |
|---|---|---|
| Price | $0.26 | $2.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 48.0K | 16.4K |
| Earning Date | 05-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,408,258.00 | N/A |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $0.23 | $1.76 |
| 52 Week High | $1.77 | $3.06 |
| Indicator | BTOC | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 48.01 |
| Support Level | $0.26 | $2.44 |
| Resistance Level | $0.33 | $2.61 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 32.77 | 71.43 |
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.